Verona Pharma, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa

This study tests a new fixed-dose combination of two drugs (ensifentrine and glycopyrrolate) given via nebulizer twice daily for 28 days in 480 adults with COPD. The goal is to see if the combination improves lung function more than either drug alone or placebo. The trial is curr…

This study tests whether a nebulized drug called ensifentrine can reduce inflammation in the lungs of people with COPD. About 56 adults aged 40-80 who smoke or have smoked will receive both the drug and a placebo at different times over 24 weeks. The main goal is to see changes i…

This study tests an inhaled drug called ensifentrine in 284 adults with non-cystic fibrosis bronchiectasis, a lung condition that causes frequent infections and breathing problems. Participants will receive either the drug or a placebo twice daily for at least 24 weeks. The goal …